GE HealthCare Technologies Inc. GEHC NDXSPX
GE HealthCare Technologies Inc. engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The Imaging segment offers molecular imaging, computed tomography (CT) scanning, magnetic resonance (MR) imaging, X-ray systems, and women's health products. The AVS segment provides ultrasound, image guided therapies, and interventional solutions for screening, diagnosis, treatment, and monitoring of certain diseases in clinical areas, such as women's health, cardiovascular, and comprehensive care ultrasound as well as surgical visualization and guidance products. The PCS segment provides medical devices, consumables, services, and digital solutions. Its portfolio includes patient monitoring, diagnostic cardiology, consumables and services, digital solutions, maternal infant care, and anesthesia products. The PDx segment supplies diagnostic agents, including CT, angiography and X-ray, MR, single-photon emission computed tomography, and positron emission tomography to the radiology and nuclear medicine industries. The segment also provides contrast media pharmaceuticals that are administered to a patient prior to certain diagnostic scans to increase the visibility of tissues or structures during imaging exams; and molecular imaging agents or radiopharmaceuticals, which are molecular tracers labeled with radioisotopes. The company has a strategic collaboration with DeepHealth. GE HealthCare Technologies Inc. was formerly known as GE Healthcare Holding LLC and changed its name to GE HealthCare Technologies Inc. in December 2022. The company was incorporated in 2022 and is headquartered in Chicago, Illinois.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Generates positive free cash flow.
CONS
- Trading 29.2% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth
No fundamental data available for this stock.
Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | GEHC GE HealthCare Technologies Inc. NDXSPX | 62.34 | 14.95 | $28.36B | 0.22% | 11.54% | 19.46% | 3.99% | 2.84% |
| 2 | LLY Eli Lilly and Company SPX | 1,105.00 | 39.21 | $985.37B | 0.63% | 38.44% | 107.46% | 31.69% | 48.96% |
| 3 | JNJ Johnson & Johnson SPX | 225.33 | 26.11 | $542.42B | 2.38% | 23.13% | 26.42% | 5.60% | 14.32% |
| 4 | UNH UnitedHealth Group Incorporated SPX | 380.31 | 28.66 | $345.38B | 2.32% | 9.60% | 12.18% | 11.35% | -15.69% |
| 5 | MRK Merck & Co., Inc. SPX | 118.72 | 33.44 | $293.22B | 2.86% | 20.66% | 18.94% | 3.12% | 7.93% |
| 6 | TMO Thermo Fisher Scientific Inc. SPX | 492.51 | 27.11 | $183.03B | 0.38% | 9.17% | 13.52% | -0.27% | -1.19% |
| 7 | AMGN Amgen Inc. NDXSPX | 336.79 | 23.42 | $181.77B | 2.99% | 18.02% | 101.32% | 11.77% | 5.58% |
| 8 | GILD Gilead Sciences, Inc. NDXSPX | 134.43 | 18.29 | $166.90B | 2.44% | 22.92% | 43.36% | 2.57% | 22.83% |
| 9 | ISRG Intuitive Surgical, Inc. NDXSPXAI | 424.64 | 51.53 | $150.39B | - | 15.96% | 17.23% | 17.39% | 29.26% |
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 4.34B | 4.48B | 4.58B | 4.71B | 4.82B | 4.82B | 4.65B | 4.84B | - | - | 4.78B | 5.01B | 5.14B | 5.70B | 5.13B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | 2.77B | 3.02B | 3.15B | 3.44B | 3.15B |
| Gross Profit | 1.68B | 1.80B | 1.77B | 1.89B | 1.94B | 1.94B | 1.90B | 2.00B | - | - | 2.01B | 1.99B | 1.99B | 2.26B | 1.98B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | 1.38B | 1.33B | 1.34B | 1.43B | 1.46B |
| Operating Income | 509.00M | 631.00M | 605.00M | 559.00M | 570.00M | 617.00M | 540.00M | 608.00M | - | - | 628.00M | 654.00M | 653.00M | 827.00M | 515.00M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | 939.00M | 874.00M | 902.00M | 1.07B | 755.00M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | 111.00M | 113.00M | 111.00M | 105.00M | 97.00M |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | 692.00M | 613.00M | 643.00M | 821.00M | 505.00M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | 104.00M | 113.00M | 179.00M | 219.00M | 94.00M |
| Net Income | 389.00M | 485.00M | 487.00M | 372.00M | 418.00M | 375.00M | 374.00M | 428.00M | - | - | 564.00M | 486.00M | 446.00M | 589.00M | 389.00M |
| Diluted EPS | 0.86 | 1.07 | 1.07 | 0.41 | 0.91 | 0.82 | 0.81 | 0.93 | - | - | 1.23 | 1.06 | 0.98 | 1.29 | 0.85 |
| R&D Expense | 238.00M | 257.00M | 260.00M | 270.00M | 298.00M | 322.00M | 324.00M | 327.00M | 316.00M | - | 344.00M | 302.00M | 292.00M | - | 345.00M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 18.34B | 19.55B | 19.67B | 20.62B |
| Cost of Revenue | - | 11.16B | 11.63B | 11.47B | 12.38B |
| Gross Profit | - | 7.18B | 7.92B | 8.21B | 8.25B |
| Operating Expenses | - | 4.66B | 5.49B | 5.58B | 5.49B |
| Operating Income | - | 2.52B | 2.44B | 2.62B | 2.76B |
| EBITDA | - | 3.23B | 3.51B | 3.67B | 3.79B |
| Interest Expense | - | 86.00M | 542.00M | 505.00M | 440.00M |
| Pretax Income | - | 2.51B | 2.36B | 2.58B | 2.77B |
| Tax Provision | - | 563.00M | 743.00M | 531.00M | 614.00M |
| Net Income | - | 1.92B | 1.57B | 1.99B | 2.08B |
| Diluted EPS | - | 4.63 | 3.03 | 4.34 | 4.55 |
| R&D Expense | 816.00M | 1.03B | 1.21B | 1.31B | 1.26B |
Compounded Sales Growth
| 5 Years: | 3.99% |
| 1 Year: | 7.40% |
Compounded Profit Growth
| 5 Years: | 2.84% |
| 1 Year: | -30.90% |
Stock Price Performance
| 1 Year: | -11.47% |
| 6 Months: | -21.97% |
| 3 Months: | -25.99% |
| 1 Month: | +4.80% |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | - | 27.54B | 32.45B | 33.09B | 36.91B |
| Current Assets | - | - | 8.32B | 9.41B | 9.90B | 12.50B |
| Cash & Equivalents | - | - | 1.44B | 2.49B | 2.87B | 4.49B |
| Inventory | - | - | 2.15B | 1.96B | 1.94B | 2.23B |
| Receivables | - | - | 3.11B | 3.34B | 3.38B | 3.72B |
| Total Liabilities | - | - | 17.95B | 25.14B | 24.44B | 26.31B |
| Current Liabilities | - | - | 7.19B | 8.98B | 9.55B | 9.11B |
| Long Term Debt | - | - | 8.23B | 8.44B | 7.45B | 9.49B |
| Total Debt | - | - | 8.63B | 9.86B | 9.38B | 10.46B |
| Total Equity | 14.75B | - | 9.36B | 7.13B | 8.45B | 10.38B |
| Shares Outstanding | - | - | 454.00M | 455.34M | 457.25M | 458.84M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 2.11B | 2.10B | 1.95B | 1.99B |
| Investing Cash Flow | - | -398.00M | -558.00M | -914.00M | -1.05B |
| Financing Cash Flow | - | -822.00M | -478.00M | -573.00M | 617.00M |
| Capital Expenditure | - | -310.00M | -387.00M | -401.00M | -482.00M |
| Free Cash Flow | - | 1.80B | 1.71B | 1.55B | 1.50B |
| Net Change in Cash | - | 893.00M | 1.06B | 464.00M | 1.56B |
| Share Buybacks | - | - | 0 | 0 | 200.00M |
| Dividends Paid | 0 | 0 | 41.00M | 55.00M | 64.00M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 39.1% | 40.5% | 41.7% | 40.0% |
| Operating Margin % | - | 13.8% | 12.5% | 13.3% | 13.4% |
| Net Margin % | - | 10.4% | 8.0% | 10.1% | 10.1% |
| ROE % | - | 20.5% | 22.0% | 23.6% | 20.1% |
| ROCE % | - | 12.4% | 10.4% | 11.2% | 9.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.91% | 35.98M | $2.24B |
| 2 | Dodge & Cox Inc. | 6.88% | 31.31M | $1.95B |
| 3 | Vanguard Capital Management LLC | 6.35% | 28.86M | $1.80B |
| 4 | Capital Research Global Investors | 4.64% | 21.11M | $1.32B |
| 5 | State Street Corporation | 4.52% | 20.54M | $1.28B |
| 6 | Vanguard Portfolio Management LLC | 4.22% | 19.18M | $1.20B |
| 7 | Harris Associates L.P. | 3.43% | 15.59M | $972.19M |
| 8 | Geode Capital Management, LLC | 2.73% | 12.40M | $772.99M |
| 9 | Barrow, Hanley Mewhinney & Strauss, LLC | 2.61% | 11.88M | $740.89M |
| 10 | Hotchkis & Wiley Capital Management, LLC | 2.19% | 9.97M | $621.40M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for GEHC